A front-of-package food label would be a great educational tool. The Trump administration should keep it.

Piper Sandler analyst Matt O'Brien increased the price target for Glaukos Corporation (NYSE:GKOS) shares to $180 from the previous target of $140, while maintaining an Overweight rating on the stock.

In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, Cantor Fitzgerald highlighted a positive outlook despite broader market uncertainties.

DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence. The full article, entitled, "Larsucosterol for the Treatment of Alcohol-Associated Hepatitis,

We recently published an article titled Jim Cramer Discusses These 18 Stocks & President Trump’s $500 Billion AI Plan. In this article, we are going to take a look at where Microsoft Corporation (NASDAQ:MSFT) stands against the other stocks Jim Cramer recently discussed.

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at where NVIDIA Corporation (NASDAQ:NVDA) stands against other best humane

The ASX 200 benchmark touched an all-time record of 8566 points before pulling back slightly. At around lunch time Friday, the index was up 0.55% to trade at 8540.

But if Kennedy hopes to target junk food ... Part of Kennedy's new mandate will include overseeing the US Food and Drug Administration (FDA), which has over 18,000 employees.

The massive, multinational corporation announced Monday that it would bend to an executive order, signed by Trump on his first day back in office, renaming the highest peak in the United States “Mount McKinley” and branding the ocean basin the “Gulf of America.”

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s adjusted earnings and revenue top analysts’ estimates. Chevron’s adjusted earnings miss expectations.

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received Fast Track designation from the U.S. Food and Drug Administration (FDA). 3

Although several companies have cut or scaled back DEI programs, Target's reversal on DEI seemed to draw the greatest outrage.